OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Douglas A. Michels sold 22,923 shares of the company’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total transaction of $527,229.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) traded down 0.40% during midday trading on Friday, hitting $22.25. 465,137 shares of the stock were exchanged. The firm has a 50-day moving average price of $21.52 and a 200 day moving average price of $17.14. The firm has a market cap of $1.32 billion, a PE ratio of 41.13 and a beta of 1.55. OraSure Technologies, Inc. has a 12-month low of $7.09 and a 12-month high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.02. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The firm had revenue of $40.18 million during the quarter, compared to the consensus estimate of $36.54 million. During the same quarter in the previous year, the company posted $0.07 EPS. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. Analysts predict that OraSure Technologies, Inc. will post $0.48 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/orasure-technologies-inc-osur-ceo-douglas-a-michels-sells-22923-shares-of-stock/1615941.html.

Hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. acquired a new position in OraSure Technologies in the 1st quarter valued at about $100,000. First Mercantile Trust Co. acquired a new position in OraSure Technologies in the 2nd quarter valued at about $104,000. Pinebridge Investments L.P. acquired a new position in OraSure Technologies in the 2nd quarter valued at about $131,000. Profund Advisors LLC acquired a new position in OraSure Technologies in the 1st quarter valued at about $137,000. Finally, BNP Paribas Arbitrage SA raised its stake in OraSure Technologies by 977.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,718 shares of the medical instruments supplier’s stock valued at $139,000 after purchasing an additional 9,723 shares during the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have weighed in on the stock. Jefferies Group LLC upped their price objective on shares of OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, June 28th. BidaskClub cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Canaccord Genuity upped their price objective on shares of OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Wednesday, September 20th. Finally, Stephens restated an “overweight” rating and set a $19.00 price objective (up from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $18.04.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.